BioSpace News Archive

Q32 Bio announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson.

Verismo Therapeutics, a clinical-stage biotechnology company and a Penn-spinout behind the novel KIR-CAR platform technology, today announced that is has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110.

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART™ leukopaks

Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options.

Life Sciences British Columbia (LSBC) announced Ali Ardakani was elected Chair of the Board of Directors. Ardakani succeeds Scott Phillips, Founder and CEO of StarFish Medical, who served as Chair of the LSBC Board for the past three years.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, announced that Clover’s contract development and manufacturing organization has received a European Union Good Manufacturing Practice certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced the appointment of Glenn E. Pauly as Head of Commercial.

Immunic, Inc. announced positive unblinded safety, tolerability and pharmacokinetic results from Part A and Part B of its phase 1 clinical trial of IMU-856 in healthy human subjects.

Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical products, announced that AC5® Advanced Wound System was selected for the “Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care” session at the 2022 Symposium on Advanced Wound Care.

Skye Bioscience, Inc. has been advised by its contract manufacturer (“CMO”) that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s Phase 1 clinical trial.